Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lens aims to sharpen sight at all distances

NCT ID NCT06258707

Symptom relief Sponsor: Cutting Edge SAS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This study tests a new type of artificial lens (LuxBoost) for people having cataract surgery. The goal is to see if it improves vision at far, middle, and close distances compared to a standard lens. About 58 adults aged 50 and older with cataracts in both eyes will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 58 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject aged 50 or over on the day of inclusion, presenting a * bilateral cataract for which posterior chamber IOL implantation * has been planned. * Fit within the available IOL diopter range. * Have had no previous refractive surgery. * Regular corneal astigmatism \< 1 dioptre by an automatic * keratometer (regularity measured by topographer). * Availability, willingness, and sufficient cognitive awareness to * comply with examination procedures. * Ability to attend all study follow-ups. * Signed informed consent. Exclusion Criteria: * Ocular surface disease potentially affecting study results * Subjects suffering from diagnosed degenerative visual disorders * Pre-existing ocular pathology * Acute or chronic disease or illness that would increase risk or confound study results * Axial lengths and keratometry such as the IOL spherical power is * not in the range of 14 to 28 D * Instability of keratometry or biometry measurements * Amblyopia * History of ocular trauma or any prior ocular surgery including refractive procedures * Capsular or zonular abnormalities that may affect postoperative centration or tilt of the lens

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aphakia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Aphakia cataract congenital primary aphakia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aphakia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinique Honore Cave

    RECRUITING

    Montauban, 82000, France

  • West Ophta

    RECRUITING

    Rennes, 35000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.